Vdyne
A clinical-stage medical technology company developing a next-generation transcatheter tricuspid valve replacement (TTVR) system designed to treat severe tricuspid regurgitation.
- CEO / Founder
- Mike Buck
- Team Size
- 11-50
- Stage
- Growth Stage
- Total Funding
- $80.2M
- Latest Round
- Series D
- Key Investors
- ["Jean Boulle Group","Undisclosed Global Medical Device Strategic Investor"]
Technology & Products
Key Products
Vdyne is developing a next-generation transcatheter tricuspid valve replacement (TTVR) system and repair technology.
Technological Advantage
Features a unique side-delivery system that allows for repositioning and recapture during deployment, along with a 'pop-off' mechanism to manage afterload mismatch, significantly reducing procedural risk.
Differentiation
Value Proposition
Provides a minimally invasive, transfemoral solution that preserves the natural asymmetric shape of the tricuspid annulus and right ventricle, offering a safer alternative for high-risk surgical patients.
How They Differentiate
Utilizes a proprietary asymmetric valve design specifically engineered to match the non-circular anatomy of the tricuspid annulus, combined with a unique side-delivery system (28 Fr) that allows for vertical crimping and full repositioning/recapture during deployment.
Market & Competition
Target Customers
Interventional cardiologists, structural heart centers, and patients suffering from severe to torrential tricuspid regurgitation (TR).
Industry Verticals
["Medical Devices","Cardiovascular Health","Structural Heart Therapy","Additive Manufacturing (MedTech)"]
Competitors
Edwards Lifesciences (EVOQUE), Abbott (TriClip/Tendyne), Medtronic (Intrepid)
Growth & Milestones
Growth Metrics
Clinical-stage with over 25 successful human cases completed across 7 global sites; currently advancing toward CE Mark approval and pivotal U.S. trials.
Major Milestones
["Series D led by Undisclosed Strategic Investor in Oct 2022","FDA Breakthrough Device Designation received in 2023","FDA Investigational Device Exemption (IDE) granted for TRIVITA1 pivotal trial in Mar 2025","Appointment of Mike Buck as Chairman and CEO to lead next phase of TTVR program in Mar 2025"]
Notable Customers
Structural Heart Centers in Australia (VISTA clinical study sites), Structural Heart Centers in Europe (VISTA clinical study sites)